Form 4: Exact Sciences EVP Orville Receives RSU Grant

Exact Sciences EVP Jacob A. Orville was granted 38,707 restricted stock units, vesting over four years.

Summary

• Jacob A. Orville, EVP, GM, Screening at Exact Sciences Corp (EXAS), reported beneficial ownership changes.
• Orville directly owns 100,403 shares of Common Stock.
• An additional 1,759 shares of Common Stock are held indirectly in a 401(k) Plan.
• Orville was granted 38,707 Restricted Stock Units (RSUs) on February 25, 2026.
• Each RSU represents a contingent right to receive one share of common stock.
• These RSUs will vest in four equal annual installments, beginning on February 25, 2027.
• In total, Orville holds 102,162 shares of Common Stock reported on this Form 4, plus an aggregate of 45,288 vested and unvested options and restricted stock units not detailed in this specific transaction.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine executive compensation event that positively aligns management's long-term interests with the company's performance and shareholder value through a multi-year vesting schedule.

Positives

• The grant of 38,707 Restricted Stock Units (RSUs) aligns executive interests with long-term shareholder value.
• The multi-year vesting schedule (four equal annual installments starting February 25, 2027) promotes executive retention and sustained performance.

Future Outlook

The granted Restricted Stock Units are scheduled to vest in four equal annual installments, commencing on February 25, 2027, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) is a common practice in the biotechnology and diagnostics industry for executive compensation, aiming to incentivize long-term performance and retention. This aligns with typical compensation structures seen across peer companies in the sector.

Comparison to Industry Standards

• RSU grants with multi-year vesting schedules are standard practice for executive compensation in the life sciences and diagnostics sector, comparable to practices at companies like Illumina (ILMN) or Guardant Health (GH).
• The size of the grant for an EVP-level executive at a company of Exact Sciences' market capitalization is generally within industry norms for incentivizing key leadership.

Stakeholder Impact

• Shareholders: The RSU grant aligns executive incentives with long-term shareholder value creation.
• Employees (Executive): Jacob A. Orville receives a significant equity grant, enhancing his compensation and long-term stake in the company.

Next Steps

• The Restricted Stock Units will vest in four equal annual installments beginning on February 25, 2027.

Key Dates

Keywords

Exact Sciences, EXAS, Jacob A. Orville, Restricted Stock Units, RSU grant, insider transaction, executive compensation, Form 4, beneficial ownership